Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Trading DecisionBuy
Generated at:2026-03-04 16:45:03
Analysis based on fundamental metrics including gross margins (66.40%), revenue growth rates (2.34%-6.46% YoY), forward P/E (20.43), technical indicators (moving averages, Bollinger Bands, RSI 63.78), debt-to-equity ratio (59.67%), and market sentiment data supporting 1-year price targets
Summary

Johnson & Johnson trading strategy overview with target price of $260.00 (6.0% upside from current $245.30), stop-loss price of $230.00, confidence level of 0.75, and risk score of 0.45 (moderate risk level).

Operation strategy
  • Accumulate on pullbacks to $240-242 range
  • Target $260 within 3-6 months
  • Partial profit-taking at $255
  • Maintain stop-loss at $230

Core Support

Reasoning summary
  • Fundamental Strength: Johnson & Johnson demonstrates robust profitability with 66.40% gross margins and consistent revenue growth (2.34%-6.46% YoY)
  • Forward P/E of 20.43 is reasonable for a healthcare leader with 65+ years of dividend growth
  • Pipeline developments like FDA Fast Track for nipocalimab and blockbuster status for Spravato ($1B+ sales) effectively offset Stelara patent expiration concerns
  • Technical Positioning: Hierarchical moving average alignment (MA5 > MA10 > MA20 > MA60) confirms bullish structure
  • Current consolidation near $245 provides entry opportunity with key support at $243.28 (20-day MA) and $235.63 (Lower Bollinger Band) limiting downside risk
  • Valuation Target: Based on fundamental analysis $250-260 range (4-6% upside), supported by news sentiment $260-270 1-year target
  • Risk Management: Stop-loss at $230.00 (6.2% downside risk, below 60-day MA major support), moderate allocation due to 50% historical stop-loss trigger rate
  • Catalysts: Immunology/neuroscience portfolio growth (Tremfya, Caplyta, Spravato), potential DePuy Synthes divestiture ($20B+ value unlock), dividend aristocrat status provides downside protection
  • Risks Mitigated: Litigation overhang priced in based on historical market response, debt levels (59.67% D/E) manageable given strong cash generation, technical indicators show consolidation not breakdown (RSI 63.78 neutral)